Next Article in Journal
Combinations of drugs in the Treatment of Obesity
Next Article in Special Issue
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Previous Article in Journal
Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders
Pharmaceuticals 2010, 3(8), 2387-2397; doi:10.3390/ph3082387
Article

Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders

1,* , 1
, 2
 and 1,2
Received: 2 June 2010; in revised form: 21 June 2010 / Accepted: 20 July 2010 / Published: 26 July 2010
(This article belongs to the Special Issue Alzheimer's Disease Drugs)
View Full-Text   |   Download PDF [182 KB, uploaded 26 July 2010]
Abstract: Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment is crucial in clinical practice and also in future clinical trials targeting disease-modifying therapies for dementia. In this article, we will first review current assessment tools for BPSD, mainly global and domain-specific scales, and new assessment methods, currently available or in development, including new scales, diagnostic criteria and new technologies such as ambulatory actigraphy.
Keywords: neuropsychiatric symptoms; assessment tools; Alzheimer’s disease; clinical trials; actigraphy neuropsychiatric symptoms; assessment tools; Alzheimer’s disease; clinical trials; actigraphy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

David, R.; Mulin, E.; Mallea, P.; Robert, P.H. Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. Pharmaceuticals 2010, 3, 2387-2397.

AMA Style

David R, Mulin E, Mallea P, Robert PH. Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders. Pharmaceuticals. 2010; 3(8):2387-2397.

Chicago/Turabian Style

David, Renaud; Mulin, Emmanuel; Mallea, Patrick; Robert, Philippe H. 2010. "Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders." Pharmaceuticals 3, no. 8: 2387-2397.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert